​

Cingulate Stock (NASDAQ:CING)

ForecastOwnershipFinancialsChart
Cingulate by TradingView

Previous Close

$4.78

52W Range

$3.16 - $11.89

50D Avg

$4.76

200D Avg

$5.07

Market Cap

$27.13M

Avg Vol (3M)

$529.74K

Beta

-0.92

Div Yield

-

CING Company Profile

Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Dec 08, 2021

Website

CING Performance

CING Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-19.94M$-15.64M$-22.76M
Net Income$-22.45M$-15.55M$-23.53M
EBITDA$-19.94M$-14.89M$-22.95M
Basic EPS$-4.13$-10.20$-311.99
Diluted EPS$-4.13$-10.20$-311.99

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
NCNANuCana plc
LEXXLexaria Bioscience Corp.
SYBXSynlogic, Inc.
BCTXBriaCell Therapeutics Corp.
ALLRAllarity Therapeutics, Inc.
CLSDClearside Biomedical, Inc.